Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Thalassemia

Thalassemia

Part of Anemia

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Thalassemia

17 trials tracked for Thalassemia: 3 in phase 3 or 4.

17Trials tracked
3Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 3 3 Phase 2 9 Phase 1 1 Other / NA 4
  1. Phase 3 Stem Cell Transplant for Hemoglobinopathy Completed
  2. Phase 3 Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload Completed
  3. Phase 3 Sildenafil to Improve Exercise Capacity in People With Thalassemia and Pulmonary Hypertension Completed
  4. Phase 2 Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs Completed
  5. Phase 2 Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension Completed
  6. Phase 2 Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload Completed
Show 11 more trials
  1. Phase 2 A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia Completed
  2. Phase 2 L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia Completed
  3. Phase 2 Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies Completed
  4. Phase 2 Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation Completed
  5. Phase 2 Extension Study to Evaluate the Safety and Efficacy of Luspatercept in Participants With β-Thalassemia Previously Enrolled in A536-04 (A536-06/MK-6143-004) Completed
  6. Phase 2 Evaluating the Safety and Effectiveness of Decitabine in People With Thalassemia Intermedia Completed
  7. Phase 1 Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders Completed
  8. N/A Zinc & Bone Health in Thalassemia: The Think Zinc Study Completed
  9. N/A Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions Completed
  10. N/A A Pilot Study of HSCT for Patients With High-risk Hemoglobinopathy Using a Nonmyeloablative Preparative Regimen Completed
  11. N/A Assessment of Pain in People With Thalassemia Completed

Showing the 17 most-cited and recently-updated of 17 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
AI-augmented screening improves hereditary hemolytic anemia detection with 92.8% pooled sensitivity
Hematology Meta-analysis
AI-augmented screening improves hereditary hemolytic anemia detection with 92.8% pooled sensitivity AI tools improve accuracy for screening hereditary blood disorders
This meta-analysis of 133,498 individuals screened for hereditary hemolytic anemia (HHA) carriers found that AI-augmented complete blood cou…
New data shows that adding artificial intelligence to blood tests can better identify people carrying genes for conditions like sickle cell …
Jun 29, 2026

Research across Anemia

Related studies from across the Anemia family.

U.S. newborn screening for alpha-thalassemia shows state-to-state variation in detection practices
Infectious Disease
U.S. newborn screening for alpha-thalassemia shows state-to-state variation in detection practices U.S. newborn screening for alpha-thalassemia varies widely between states
A report on U.S. newborn screening programs found that practices for detecting alpha-thalassemia vary between states.
Whether a newborn gets tested for alpha-thalassemia depends on which state they are born in, as screening rules vary widely across the U.S.
CDC Apr 6, 2026